DeepaBhojwaniMD

Physician

Dr. Bhojwani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

NYU Grossman School of MedicineFellowship, Pediatric Hematology/Oncology, 2001 - 2004
Woodhull Medical and Mental Health CenterResidency, Pediatrics, 1998 - 2001
M.S. Ramaiah Medical CollegeClass of 1994

PubMed

Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic Ethnicity.
Maud Maillard, Jenny Q Nguyen, Wenjian Yang, Keito Hoshitsuki, Mary V Relling
Clinical Pharmacology and Therapeutics. 2024-12-17
CD33-CD123 IF-THEN gating reduces toxicity while enhancing the specificity and memory phenotype of AML-targeting CAR-T cells.
Samy Jambon, Jianping Sun, Shawn Barman, Sakunthala Muthugounder, Xue Rachel Bito
Blood Cancer Discovery. 2024-12-03
Pediatric therapy-related hematologic neoplasms show enrichment forrearrangement and lymphoblastic phenotype.
Alexandra E Kovach, Daria Komova, Albert Itov, Maria Gaskova, Irina Kalinina
Leukemia & Lymphoma. 2024-12-01

Journal Articles

Inotuzumab Ozogamicin in Pediatric Patients with relapsed/refractory Acute Lymphoblastic Leukemia
Deepa Bhojwani, Constance Yuan, Jennifer L McNeer, Mignon L Loh, Vilmarie Rodriguez, Susan R Rheingold, Elizabeth A Raetz, Nature

Abstracts/Posters

Targeting of Integrin _4/VCAM-1 with AVA4746 Modulates the Redox-Status and Metabolism in ALL and Angiogenesis
Deepa Bhojwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy
Deepa Bhojwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
Deepa Bhojwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML:...
Deepa Bhojwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

First Edition: March 12, 2021March 12th, 2021
‘An Accelerated Cauldron of Evolution’: Covid-19 Patients with Cancer, HIV, May Play a Role in Emergence of VariantsMarch 11th, 2021
Can a Novel Approach Lead to Less-Toxic Treatments for Leukemia?December 2nd, 2023